Compare AZN Stock to Peers
|Symbol||Last Price||Market Cap||% Δ 1 Yr||% Δ 5 Yr|
News & Analysis: AstraZeneca PLC
It may not be a matter of if, but a matter of how high.
The company's next-generation treatment for breast cancer could become the new standard of care.
You don't need a giant pile of cash to generate a healthy return from this trio of growth, value, and income stocks.
The pharma giant recently received approval to market Forxiga as a treatment for chronic kidney disease patients in Japan.
Even though AstraZeneca and FibroGen must now conduct an additional safety trial to have a chance at FDA approval, not all is lost.
The recent decision by the EMA to approve Forxiga for the treatment of chronic kidney disease is a huge boost for the pharmaceutical company.
Each of these companies makes for a great vehicle to play an aging demographic.
Even if you aren't crazy about the company's COVID-19 vaccine, this is still a growth investment worth considering for your portfolio.
The FDA recently approved Ultomiris as a treatment for paroxysmal nocturnal hemoglobinuria patients who are under 18, and it should get a similar label expansion in the E.U. soon.